As in our cohort no patient apart from SF3B1 was included with MDS-defining cytogenetic or molecular aberrations such as del(5q) or biallelic TP53 there was no assignment to the respective subgroups by WHO 2022. Here, TP53 is linked to myelodysplastic syndrome.